Potentiation of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica following its co-administration with the metabolic inhibitor, ketoconazole

Veterinary Parasitology

Volumn 184, Issue 1, 2012, Pages 37-47

  Devine, C ^a   Brennan, G P ^a   Lanusse, C E ^b   Alvarez, L I ^b   Trudgett, A ^a   Hoey, E ^a   Fairweather, I ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSIDAD NACIONAL DEL CENTRO DE LA PROVINCIA DE BUENOS AIRES   (Argentina)

Author keywords

Fasciola hepatica; Ketoconazole; Liver fluke; Transmission electron microscopy; Triclabendazole resistance

Indexed keywords

GLYCOSAMINOGLYCAN; KETOCONAZOLE; TRICLABENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APICAL MEMBRANE; ARTICLE; CELL SWELLING; CONTROLLED STUDY; DRUG POTENTIATION; FASCIOLA HEPATICA; FASCIOLIASIS; GOLGI COMPLEX; IN VIVO STUDY; INFECTION CONTROL; INTEGUMENT; MITOCHONDRION; NONHUMAN; PARASITE ISOLATION; RAT; SECRETORY VESICLE; SYNCYTIUM; TRANSMISSION ELECTRON MICROSCOPY;

14-ALPHA DEMETHYLASE INHIBITORS; ANIMALS; ANTHELMINTICS; BENZIMIDAZOLES; DRUG RESISTANCE; DRUG SYNERGISM; FASCIOLA HEPATICA; FASCIOLIASIS; KETOCONAZOLE; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; RATS;

FASCIOLA HEPATICA; RATTUS; RATTUS NORVEGICUS;

EID: 84855306129     PISSN: 03044017     EISSN: 18732550     Source Type: Journal    
DOI: 10.1016/j.vetpar.2011.08.006     Document Type: Article

References (63)

1. Alvarez L.I., Solana H.D., Mottier M.L., Virkel G.L., Fairweather I., Lanusse C.E. Altered drug influx/efflux and enhanced metabolic activity in triclabendazole-resistant liver flukes. Parasitology 2005, 131:501-510.
2. Alvinerie M., Dupuy J., Kiki-Mvouaka S., Sutra J.-F., Lespine A. Ketoconazole increases the plasma levels of ivermectin in sheep. Vet. Parasitol. 2008, 157:117-122.
3. Anderson H.R., Fairweather I. Fasciola hepatica: ultrastructural changes to the tegument of juvenile flukes following incubation in vitro with the deacetylated (amine) metabolite of diamphenethide. Int. J. Parasitol. 1995, 25:319-333.
4. Benchaoui H.A., McKellar Q.A. Interaction between fenbendazole and piperonyl butoxide: pharmacokinetic and pharmacodynamic implications. J. Pharm. Pharmacol. 1996, 48:753-759.
5. Coles G.C., Stafford K.A. Activity of oxyclozanide, nitroxynil, clorsulon and albendazole against adult triclabendazole-resistant Fasciola hepatica. Vet. Rec. 2001, 148:723-724.
6. Coles G.C., Rhodes A.C., Stafford K.A. Activity of closantel against adult triclabendazole-resistant Fasciola hepatica. Vet. Rec. 2000, 146:504.
7. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Effect of the metabolic inhibitor, methimazole on the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitology 2009, 136:183-192.
8. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Inhibition of cytochrome P450-mediated metabolism enhances ex vivo susceptibility of Fasciola hepatica to triclabendazole. Parasitology 2010, 137:871-880.
9. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Potentiation of triclabendazole sulphoxide-induced tegumental disruption by methimazole in a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol. Res. 2010, 106:1351-1363.
10. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E., Fairweather I. Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole. Parasitol. Res. 2010, 107:337-353.
11. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E.M., Fairweather I. Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica. Parasitology 2011, 138:224-236.
12. Devine C., Brennan G.P., Lanusse C.E., Alvarez L.I., Trudgett A., Hoey E.M., Fairweather I. Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole. Vet. Parasitol. 2011, 177:305-315.
13. Devine, C., Brennan, G.P., Lanusse, C.E., Alvarez, L.I., Trudgett, A., Hoey, E., Fairweather, I. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica. Parasitol. Res., , in press. doi:10.1007/s00436-011-2304-9.
14. Dupuy J., Larrieu G., Sutra J.F., Lespine A., Alvinerie M. Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol. 2003, 112:337-347.
15. Fairweather I. Triclabendazole: new skills to unravel an old(ish) enigma. J. Helminthol. 2005, 79:227-234.
16. Fairweather I. Triclabendazole progress report, 2005-2009: an advancement of learning?. J. Helminthol. 2009, 83:139-150.
17. Fairweather I. Liver fluke isolates: a question of provenance. Vet. Parasitol. 2011, 176:1-8.
18. Fairweather I. Reducing the future threat from (liver) fluke: realistic prospect or quixotic fantasy?. Vet. Parasitol. 2011, 180:133-143.
19. Fairweather I. Raising the bar on reporting cases of triclabendazole resistance. Vet. Rec. 2011, 168:514-515.
20. Fairweather I., Anderson H.R., Threadgold L.T. Fasciola hepatica: tegumental changes induced in vitro by the deacetylated (amine) metabolite of diamphenethide. Exp. Parasitol. 1986, 62:336-348.
21. Fairweather I., Threadgold L.T., Hanna R.E.B. Development of Fasciola hepatica in the mammalian host. Fasciolosis 1999, 47-111. CAB International, Wallingford, Oxon, UK. J.P. Dalton (Ed.).
22. Fairweather I., Meaney M., Savage J., Brennan G., Hoey E., Trudgett A. Do drug efflux pumps play a role in the resistance of Fasciola hepatica to triclabendazole?. 23rd International Conference of the WAAVP 2009, Abst. CS35.2.
23. Flanagan A.M., Edgar H.W.J., Forster F., Gordon A., Hanna R.E.B., McCoy M., Brennan G.P., Fairweather I. Standardisation of a coproantigen reduction test (CRT) protocol for the diagnosis of resistance to triclabendazole in Fasciola hepatica. Vet. Parasitol. 2011, 176:34-42.
24. Flanagan A., Edgar H.W.J., Gordon A., Hanna R.E.B., Brennan G.P., Fairweather I. Comparison of two diagnostic assays, a faecal egg count reduction test (FECRT) and a coproantigen reduction test (CRT), for the diagnosis of resistance to triclabendazole in Fasciola hepatica in sheep. Vet. Parasitol. 2011, 176:170-176.
25. Fox N.J., White P.C.L., McClean C.J., Marion G., Evans A., Hutchings M.R. Predicting impacts of climate change on Fasciola hepatica risk. PLoS One 2011, 6:e16126.
26. Gaasenbeek C.P.H., Moll L., Cornelissen J.B.W.J., Vellema P., Borgsteede F.H.M. An experimental study on triclabendazole resistance of Fasciola hepatica in sheep. Vet. Parasitol. 2001, 95:37-43.
27. Halferty L., Brennan G.P., Trudgett A., Hoey E.M., Fairweather I. The relative activity of triclabendazole metabolites against the liver fluke, Fasciola hepatica. Vet. Parasitol. 2009, 159:126-138.
28. Hanna R.E.B., Edgar H.W.J., McConnell S., Toner E., McConville M., Brennan G.P., Devine C., Flanagan A., Halferty L., Meaney M., Shaw L., Moffett D., McCoy M., Fairweather I. Fasciola hepatica: histological changes in the reproductive structures of triclabendazole (TCBZ)-sensitive and TCBZ-resistant flukes collected from experimentally-infected sheep one to four days after treatment with TCBZ and the related benzimidazole derivative, Compound Alpha. Vet. Parasitol. 2010, 168:240-254.
29. Hennessy D.R., Lacey E., Steel J.W., Prichard R.K. The kinetics of triclabendazole disposition in sheep. J. Vet. Pharmacol. Ther. 1987, 10:64-72.
30. Kenyon F., Sargison N.D., Skuce P.J., Jackson F. Sheep helminth parasitic disease in south eastern Scotland arising as a possible consequence of climate change. Vet. Parasitol. 2009, 163:293-297.
31. Lanusse C.E., Prichard R.K. Clinical pharmacokinetics and metabolism of benzimidazole anthelmintics in ruminants. Drug Metab. Rev. 1993, 25:235-279.
32. Lanusse C.E., Gascon L.H., Prichard R.K. Influence of the antithyroid compound methimazole on the plasma disposition of fenbendazole and oxfendazole in sheep. Res. Vet. Sci. 1995, 58:222-226.
33. López-García M.L., Torrado S., Torrado S., Martínez A.R., Bolás F. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of Trichinella spiralis in mice: the influence of the dose-regime. Vet. Parasitol. 1998, 75:209-219.
34. McConville M., Brennan G.P., Flanagan A., Edgar H.W.J., McCoy M., Castillo R., Hernández-Campos A., Fairweather I. Surface and internal tegumental changes in juvenile Fasciola hepatica following treatment in vivo with the experimental fasciolicide, compound alpha. Vet. Parasitol. 2008, 153:52-64.
35. McConville M., Brennan G.P., Flanagan A., Edgar H.W.J., Hanna R.E.B., McCoy M., Gordon A.W., Castillo R., Hernández-Campos A., Fairweather I. An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica. Vet. Parasitol. 2009, 162:75-88.
36. McConville M., Brennan G.P., Flanagan A., Edgar H.W.J., Castillo R., Hernández-Campos A., Fairweather I. Ultrastructural changes to the tegumental system and the gastrodermal cells in adult Fasciola hepatica following in vivo treatment with the experimental fasciolicide, compound alpha. Parasitology 2009, 136:665-680.
37. McKinstry B., Brennan G.P., Halferty L., Forbes A.B., Fairweather I. Ultrastructural changes induced in the tegument and gut of Fasciola hepatica following in vivo and in vitro drug treatment with nitroxynil (Trodax). Parasitol. Res. 2007, 101:929-941.
38. McKinstry B., Halferty L., Brennan G.P., Fairweather I. Morphological response of triclabendazole-resistant isolates of Fasciola hepatica to treatment in vitro with nitroxynil (Trodax). Parasitol. Res. 2009, 104:645-655.
39. Meaney M., Fairweather I., Brennan G.P., Forbes A.B. Transmission electron microscope study of the ultrastructural changes induced in the tegument and gut of Fasciola hepatica following treatment with clorsulon. Parasitol. Res. 2004, 92:232-241.
40. Meaney M., Allister J., McKinstry B., McLauglin K., Brennan G.P., Forbes A.B., Fairweather I. Fasciola hepatica: ultrastructural effects of a combination of triclabendazole and clorsulon against mature fluke. Parasitol. Res. 2007, 100:1091-1104.
41. Moll L., Gaasenbeek C.P.H., Vellema P., Borgsteede F.H.M. Resistance of Fasciola hepatica against triclabendazole in cattle and sheep in The Netherlands. Vet. Parasitol. 2000, 91:153-158.
42. Mooney L., Good B., Hanrahan J.P., Mulcahy G., de Waal T. The comparative efficacy of four anthelmintics against a natural acquired Fasciola hepatica infection in hill sheep flock in the west of Ireland. Vet. Parasitol. 2009, 164:201-205.
43. Mottier L., Alvarez L., Ceballos L., Lanusse C. Drug transport mechanisms in helminth parasites: passive diffusion of benzimidazole anthelmintics. Exp. Parasitol. 2006, 113:49-57.
44. Mottier L., Alvarez L., Fairweather I., Lanusse C. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. J. Parasitol. 2006, 92:1355-1360.
45. Olaechea F., Lovera V., Larroza M., Raffo F., Cabrera R. Resistance of Fasciola hepatica against triclabendazole in cattle in Patagonia (Argentina). Vet. Parasitol. 2011, 178:364-366.
46. Overend D.J., Bowen F.L. Resistance of Fasciola hepatica to triclabendazole. Aust. Vet. J. 1995, 72:275-276.
47. Robinson M.W., Trudgett A., Hoey E.M., Fairweather I. Triclabendazole-resistant Fasciola hepatica: β-tubulin and response to in vitro treatment with triclabendazole. Parasitology 2002, 124:325-338.
48. Robinson M.W., Lawson J., Trudgett A., Hoey L., Fairweather I. The comparative metabolism of triclabendazole sulphoxide by triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica. Parasitol. Res. 2004, 92:205-210.
49. Ryan L.A., Hoey E., Trudgett A., Fairweather I., Fuchs M., Robinson M.W., Chambers E., Timson D., Ryan E., Fetwell T., Ivens A., Bentley G., Johnston D. Fasciola hepatica expresses multiple α- and β-tubulin isotypes. Mol. Biochem. Parasitol. 2008, 159:73-78.
50. Sánchez-Bruni S.F.S., Fusé L.A., Moreno L., Saumell C.A., álvarez L.I., Fiel C., McKellar Q.A., Lanusse C.E. Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. Equine Vet. J. 2005, 37:257-262.
51. Skuce P.J., Anderson H.R., Fairweather I. The interaction between the deacetylated (amine) metabolite of diamphenethide (DAMD) and cytochemically demonstrable Na+/K+-ATPase activity in the tegument of Fasciola hepatica. Parasitol. Res. 1987, 74:161-167.
52. Skuce P.J., Fairweather I. The effect of the hydrogen ionopore closantel upon the pharmacology and ultrastructure of the adult fluke Fasciola hepatica. Parasitol. Res. 1990, 76:241-250.
53. Threadgold L.T., Brennan G.P. Fasciola hepatica: basal infolds and associated vacuoles of the tegument. Exp. Parasitol. 1978, 46:300-316.
54. Toner E., McConvery F., Brennan G.P., Meaney M., Fairweather I. A scanning electron microscope study on the route of entry of triclabendazole into the liver fluke Fasciola hepatica. Parasitology 2009, 126:523-535.
55. Toner E., McConvery F., Brennan G.P., Meaney M., Fairweather I. A transmission electron microscope study on the route of entry of triclabendazole into the liver fluke, Fasciola hepatica. Parasitology 2010, 137:855-870.
56. Toner E., Brennan G.P., Hanna R.E.B., Edgar H.W., Fairweather I. Tegumental surface changes in adult Fasciola hepatica in response to treatment in vivo with triclabendazole in the sheep host. Vet. Parasitol. 2010, 172:238-248.
57. Toner E., Brennan G.P., Hanna R.E.B., Edgar H.W., Fairweather I. Time-dependent changes to the tegumental system and gastrodermis of adult Fasciola hepatica following treatment in vivo with triclabendazole in the sheep host. Vet. Parasitol. 2010, 174:218-227.
58. Toner E., Brennan G.P., Hanna R.E.B., Edgar H.W.J., Fairweather I. Disruption of egg formation by Fasciola hepatica following treatment in vivo with triclabendazole in the sheep host. Vet. Parasitol. 2011, 177:79-89.
59. Toner, E., Brennan, G.P., Hanna, R.E.B., Edgar, H.W.J., Fairweather, I. Fasciola hepatica: time-dependent disruption of spermatogenesis following in vivo treatment with triclabendazole. Parasitol. Res., , in press. doi:10.1007/s00436-011-2341-4.
60. Van Dijk J., Sargison N.D., Kenyon F., Skuce P.J. Climate change and infectious disease: helminthological challenges to farmed ruminants in temperate regions. Animal 2010, 4:377-392.
61. Virkel G., Lifschitz A., Sallovitz J., Pis A., Lanusse C. Assessment of the main metabolism pathways for the flukicidal compound triclabendazole in sheep. J. Vet. Pharmacol. Ther. 2006, 29:213-223.
62. Virkel G., Lifschitz A., Sallovitz J., Ballent M., Scarcella S., Lanusse C. Inhibition of cytochrome P450 activity enhances the systemic availability of triclabendazole metabolites in sheep. J. Vet. Pharmacol. Ther. 2009, 32:79-86.
63. Walker S.M., McKinstry B., Boray J.C., Brennan G.P., Trudgett A., Hoey E.M., Fletcher H., Fairweather I. Response of two isolates of Fasciola hepatica to treatment with triclabendazole in vivo and in vitro. Parasitol. Res. 2004, 94:427-438.